美国 · 平台与数据 · The Motley Fool

Where Will Neurocrine Biosciences Be in 5 Years?

来源：The Motley Fool · 美国 1 小时前

Neurocrine's expanding drug portfolio could drive substantial growth through 2031.

在 The Motley Fool 阅读全文登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.fool.com)

推荐阅读

Kardigan, Inc. (NASDAQ:KARD) Stock Now Rated "Moderate Buy" by Wall Street Brokerages

Best Stocks to Day Trade

Explainer-How Ukraine’s strikes on Russian energy sites deepened the rift with Trump

Jamie Dimon warns of 5 big threats to the US economy — how America’s biggest bank is protecting itself now (copy them)

Soaring Oil Prices Could Benefit These 2 ‘Strong Buy’ Energy Stocks

Audi to build $4.2B auto plant in Georgia, pledging long-term investment in U.S. market